Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:KZIA NASDAQ:NRSN NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-0.5%$2.27$1.65▼$3.07$23.07M0.2421,464 shs15,344 shsKZIANovogen$13.25$13.11$4.86▼$17.40$21.86M2.14143,202 shs116,099 shsNRSNNeuroSense Therapeutics$0.71$0.79$0.63▼$2.19$23.05M1.58220,866 shs231,763 shsSNGXSoligenix$0.39$0.50$0.28▼$6.23$5.74M1.921.41 million shs841,146 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%-0.92%-4.44%-19.17%-11.34%KZIANovogen0.00%-8.18%+20.56%+80.52%+94.25%NRSNNeuroSense Therapeutics0.00%-6.52%-5.61%-7.09%-62.93%SNGXSoligenix0.00%-5.61%-12.70%-66.05%-67.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-0.5%$2.27$1.65▼$3.07$23.07M0.2421,464 shs15,344 shsKZIANovogen$13.25$13.11$4.86▼$17.40$21.86M2.14143,202 shs116,099 shsNRSNNeuroSense Therapeutics$0.71$0.79$0.63▼$2.19$23.05M1.58220,866 shs231,763 shsSNGXSoligenix$0.39$0.50$0.28▼$6.23$5.74M1.921.41 million shs841,146 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%-0.92%-4.44%-19.17%-11.34%KZIANovogen0.00%-8.18%+20.56%+80.52%+94.25%NRSNNeuroSense Therapeutics0.00%-6.52%-5.61%-7.09%-62.93%SNGXSoligenix0.00%-5.61%-12.70%-66.05%-67.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 2.25Hold$10.75400.00% UpsideKZIANovogen 2.67Moderate Buy$25.8094.72% UpsideNRSNNeuroSense Therapeutics 2.60Moderate Buy$8.501,100.56% UpsideSNGXSoligenix 2.00Hold$6.001,450.39% UpsideCurrent Analyst Ratings BreakdownLatest SNGX, NRSN, KZIA, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026KZIANovogen BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.006/11/2026AYTUAytu BioPharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $14.506/11/2026KZIANovogen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.005/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/8/2026NRSNNeuroSense Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNGXSoligenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$66.38M0.35$0.37 per share5.75$2.11 per share1.02KZIANovogen$30K728.75N/AN/A($5.34) per share-2.48NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/ASNGXSoligenix$120K47.79N/AN/A$0.52 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$13.56M-$4.58N/A8.60N/A-60.17%-69.93%-13.25%9/22/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)NRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)SNGXSoligenix-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)Latest SNGX, NRSN, KZIA, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million5/8/2026Q1 2026SNGXSoligenix-$0.30-$0.28+$0.02-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.121.00KZIANovogenN/A2.87N/ANRSNNeuroSense TherapeuticsN/A0.310.31SNGXSoligenixN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%KZIANovogen30.89%NRSNNeuroSense Therapeutics1.04%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma4.90%KZIANovogen1.00%NRSNNeuroSense Therapeutics27.40%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataNRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionableSNGXSoligenix2014.82 million14.37 millionNot OptionableSNGX, NRSN, KZIA, and AYTU HeadlinesRecent News About These CompaniesSoligenix Expands At-the-Market Equity Offering CapacityJune 26, 2026 | tipranks.comSoligenix Inc. (NASDAQ:SNGX) Short Interest Down 92.6% in JuneJune 26, 2026 | americanbankingnews.comSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineJune 8, 2026 | prnewswire.comSoligenix Expands At-The-Market Equity Financing CapacityMay 28, 2026 | tipranks.comSNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail FrenzyMay 27, 2026 | finance.yahoo.comSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoMay 26, 2026 | prnewswire.comSOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deSoligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | prnewswire.comSNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatmentApril 29, 2026 | msn.comSNGX phase 3 trial halted on HyBryteApril 29, 2026 | msn.comSOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | finanznachrichten.deSNGX phase 3 trial halted — HyBryte setback puts strategy in questionApril 28, 2026 | msn.comSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | prnewswire.comSoligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | usatoday.comSoligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | financial-news.co.ukSoligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study ResultsApril 17, 2026 | financial-news.co.ukSoligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsApril 17, 2026 | finance.yahoo.comSoligenix (SNGX) price target decreased by 14.29% to 15.30April 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNGX, NRSN, KZIA, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.15 -0.01 (-0.46%) Closing price 07/2/2026 03:56 PM EasternExtended Trading$2.16 +0.01 (+0.47%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Novogen NASDAQ:KZIA$13.25 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$13.40 +0.15 (+1.16%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.NeuroSense Therapeutics NASDAQ:NRSN$0.71 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.71 +0.00 (+0.28%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Soligenix NASDAQ:SNGX$0.39 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.40 +0.01 (+2.33%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
